Hematologic disorder: Hemolytic anaemia - with reticulocytosis; or leucopoenia - less than 3,500/mm3 on two (2) or more occasions; or thrombocytopenia - less than 100,000mm3 in the absence of offending drugs. Immunologic disorder: Positive LE cell preparation; or anti-DNA: antibody to native DNA in abnormal titre; or anti-Sm: presence of antibody to Sm (Smooth Muscle) nuclear antigen; or false positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema pallidum immobilisation or fluorescent treponemal antibody absorption test. Antinuclear antibody: An abnormal titre of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with ‘drug-induced lupus' syndrome. Alopecia: diffuse thinning and fragility of the hair in the absence of other causes (such as alopecia areata, drugs, iron deficiency and androgenic alopecia). In addition to the diagnosis of systemic lupus erythematosus, lupus nephritis must be confirmed by renal changes as measured by a renal biopsy that it is grade 3 to 5 of the World Health Organisation (WHO) classification of lupus nephritis and be associated with persisting proteinuria (more than 2+). Systemic Sclerosis The life assured has been unequivocally diagnosed by an appropriate specialist with systemic sclerosis, causing the life assured to be totally and irreversibly unable to perform any one (1) of the activities of daily living without assistance of another adult person. Terminal illness The life assured has been diagnosed as having an illness where in AIA’s opinion despite all reasonable medical treatment they are expected to live for no more than 12 months. The registered medical practitioner treating the illness must provide supporting evidence of the illness, possible medical treatment, the prognosis and confirm that the definition of Terminal Illness has been met. The claim payment will be paid if the life assured is alive 14 days following the medical certification. The Terminal Illness Benefit will be treated as an early payment of the Critical Conditions Benefit. The Critical Conditions Benefit will then be reduced by any amount paid by the Terminal Illness Benefit. This Benefit is only available if the words “Standalone Critical Conditions Cover” appears in the schedule . Death of the life assured as a result of accident is not covered under the Terminal Illness Benefit.
tissue swelling or fluid;
Joint deformity typical of rheumatoid arthritis;
Rheumatoid nodules beneath the skin;
X-ray imaging showing erosion to joints typical of rheumatoid arthritis.
Degenerative osteoarthritis and all other arthritides are excluded.
The benefit payable is:
25% of the sum assured up to a maximum of $75,000 across all Business AIA policies for the life assured, if the unequivocal diagnosis occurs before the life assured is 50 years of age; or 25% of the sum assured up to a maximum of $10,000 across all Business AIA policies for the life assured, if the unequivocal diagnosis occurs after the life assured is over 50 years of age. Severe ulcerative colitis A life assured has been unequivocally diagnosed by an appropriate specialist with ulcerative colitis that requires permanent immunosuppressive medication or as a result of the diagnosis has undergone a surgical procedure to remove the entire large bowel. The benefit payable is 25% of the sum assured to a maximum of $75,000 across all Business AIA policies for the life assured . Systemic Lupus Erythematosus with lupus nephritis The life assured has been unequivocally diagnosed by an appropriate specialist with systemic lupus erythematosus with lupus nephritis in the clinical setting, evidenced by the presence of any four or more of the following twelve criteria: Malar rash: Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds. Discoid rash: Erythematosus, raised patches with adherent kerotic scaling and follicular plugging, atrophic scarring may occur in older lesions. Photosensitivity: Skin rash as a result of unusual reaction to sunlight, evidenced by patient history or specialist’s report. Oral ulcers: Oral or nasopharyngeal ulceration reported by physician. Arthritis: Non-erosive arthritis involving two or more peripheral joints, characterised by tenderness, swelling, or effusion. Serositis: Pleuritis - convincing history of pleuritic pain or pleuritic rub heard by a physician or evidence of pleural effusion; or pericarditis - documented by ECG or rub or evidence of pericardial effusion. Renal disorder: Persistent proteinuria greater than 0.5 grams per day; or greater than 2+ if quantitation not performed; or tubular casts - may be red cell, haemoglobin, granular, cellular or mixed. Neurological disorder: Seizures - in the absence of offending drugs or known metabolic derangements, e.g. uraemia, ketoacidosis; or electrolyte imbalance.
1155 ALB-CC version 8 Effective 12 May 2026
Page 22 of 25
Powered by FlippingBook